David Scott Moore, Director at Corvus Pharmaceuticals, Inc. (CRVS), bought 21,700 shares at $11.53 ($250K) on 2026-06-11, disclosed to the SEC on 2026-06-15.
Director David Scott Moore purchased 21,700 shares at $11.53, marking the largest insider purchase in the company's history. This move follows a 22.5% decline over the last 90 days, potentially signaling conviction in the biotech's pipeline despite recent volatility.
CRVS is currently trading at $11.94, up 7.2% over the last five days but down 22.5% over the trailing 90 days. The stock remains 55.7% below its 52-week high of $26.95, offering a potential entry point for buyers.
Investors should monitor for anticipated Phase 2 data for soquelitinib in atopic dermatitis and ongoing discussions regarding the company as a potential M&A target. Additionally, this trade represents the largest insider purchase in the company's history, signaling strong conviction from leadership.
The stock carries significant risk with a short interest of 23.42% of the float, indicating heavy bearish positioning. Furthermore, the company reported a first-quarter 2026 net loss of $13.69 million, reversing from a prior year profit.
Something here stands out, but not much.